LLM 2021 | Future directions for CAR T-cell therapy in MCL
Natalie Grover
• 15 Oct 2021
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, explains that Bruton’s tyrosine kinase (BTK) inhibitors continue to be the first-choice treatment, but CAR T-cell therapy has gained prominence in mantle cell lymphoma (MCL) since the approval of brexucabtagene autoleucel for second line. In high-response patients, CAR T-cells could be considered in earlier lines, given that the performance CAR T-cells was similar in groups with both high and less-high response features, like blastoid MCL or TP53 mutations. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech
